Allogene Therapeutics
Leslie Torres-Bryant is a seasoned communications professional with extensive experience in the healthcare sector. Currently serving as a Senior Communications Consultant at Allogene Therapeutics since April 2022, Torres-Bryant also operates as Principal at LAB Consulting, a healthcare strategy and communications consultancy founded in April 2011. Previous roles include Group Senior Vice President at RXMOSAIC, Executive Director of Communications at Dendreon, and Senior Consultant at W2O Group, among others. With a background that includes vice president positions at Hill and Knowlton and corporate communications management at Allergan Pharmaceuticals, Torres-Bryant has built a robust career in healthcare communications, supported by a Bachelor of Arts degree in Journalism/PR from California State University, Long Beach.
This person is not in any teams
This person is not in any offices
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.